Table 2. Univariate metaregression analysis of possible sources of heterogeneity across studies.
| Possible source of heterogeneity | Adjusted-R2 (%)a | Pb |
|---|---|---|
| No. of patients | 0.3 | 0.301 |
| Ethnicity (Asian or not) | 61.78 | 0.033 |
| Study design (multi- or single-center cohort) | 87.86 | 0.042 |
| Age | −9.30 | 0.310 |
| Age < 18 y (%) | −28.77 | 0.627 |
| Follow-up time (months) | 14.74 | 0.152 |
| Male/female | −10.84 | 0.465 |
| Hypertension (%) | −14.07 | 0.281 |
| Immunosuppressive therapy (%) | −35.70 | 0.926 |
| Treatment with RASBs (%) | −36.04 | 0.682 |
| End point eventc number | −2.84 | 0.351 |
aProportion of between-study variance explained by covariates.
bP value derived from the joint test for all covariates with Knapp–Hartung modification.
cEnd-stage kidney disease (ESRD), >50% decrease in estimated glomerular filtration rate (eGFR), or doubling of serum creatinine concentration.